BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 23196701)

  • 1. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
    Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
    Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
    van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
    Lancet; 2009 Aug; 374(9688):459-66. PubMed ID: 19665644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
    Eriksson JK; Karlsson JA; Bratt J; Petersson IF; van Vollenhoven RF; Ernestam S; Geborek P; Neovius M
    Ann Rheum Dis; 2015 Jun; 74(6):1094-101. PubMed ID: 24737786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pain Over Two Years After Start of Biologic Versus Conventional Combination Treatment in Early Rheumatoid Arthritis: Results From a Swedish Randomized Controlled Trial.
    Olofsson T; Wallman JK; Jöud A; Schelin MEC; Ernestam S; van Vollenhoven R; Saevarsdottir S; Lampa J
    Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1312-1321. PubMed ID: 32433827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.
    Eriksson JK; Neovius M; Bratt J; Petersson IF; van Vollenhoven RF; Geborek P; Ernestam S
    JAMA Intern Med; 2013 Aug; 173(15):1407-14. PubMed ID: 23817631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial.
    Levitsky A; Forslind K; van Vollenhoven RF;
    Scand J Rheumatol; 2015; 44(5):348-53. PubMed ID: 25992914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE; Bochkova AG; Bunchuk NV
    Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA.
    Lie E; Uhlig T; van der Heijde D; Rødevand E; Kalstad S; Kaufmann C; Mikkelsen K; Kvien TK
    Rheumatology (Oxford); 2012 Apr; 51(4):670-8. PubMed ID: 22157597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
    van Vollenhoven RF; Geborek P; Forslind K; Albertsson K; Ernestam S; Petersson IF; Chatzidionysiou K; Bratt J;
    Lancet; 2012 May; 379(9827):1712-20. PubMed ID: 22464340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine.
    Miller H; Wallman JK; Petersson IF; Saevarsdottir S; Söderling J; Ernestam S; Askling J; van Vollenhoven R; Neovius M
    Rheumatology (Oxford); 2021 May; 60(5):2217-2222. PubMed ID: 33179071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.
    O'Dell JR; Petersen K; Leff R; Palmer W; Schned E; Blakely K; Haire C; Fernandez A
    J Rheumatol; 2006 Feb; 33(2):213-8. PubMed ID: 16358366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial.
    Levitsky A; Erlandsson MC; van Vollenhoven RF; Bokarewa MI
    BMC Med; 2015 Sep; 13():247. PubMed ID: 26420684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
    Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
    Ann Rheum Dis; 2016 Feb; 75(2):356-61. PubMed ID: 25550338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?
    Schipper LG; Fransen J; Barrera P; den Broeder AA; Van Riel PL
    Rheumatology (Oxford); 2009 Oct; 48(10):1247-53. PubMed ID: 19638454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial.
    Tam LS; Shang Q; Li EK; Wang S; Li RJ; Lee KL; Leung YY; Ying KY; Yim CW; Kun EW; Leung MH; Li M; Li TK; Zhu TY; Chui RK; Tseung L; Yu SL; Kuan WP; Yu CM
    J Rheumatol; 2012 Dec; 39(12):2267-75. PubMed ID: 22984272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.